Mimedx (MDXG) Non-Current Deferred Tax Liability (2016)
Mimedx recorded quarterly Non-Current Deferred Tax Liability of $1.1 million in Q4 2016.
Mimedx's Non-Current Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $1.1 million for Q4 2016.
- In Q4 2016, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million; the TTM figure through Dec 2016 stood at $1.1 million (changed N/A YoY), while the FY2016 annual figure was $1.1 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability came in at $1.1 million for Q4 2016 at Mimedx.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2016 to a low of $1.1 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 1.13 Mn |
| Dec 31, 2016 | 1.13 Mn |